As global health threats continue to evolve rapidly, pharmaceutical leaders face mounting pressure to design development programs that can withstand volatility. From pandemics to geopolitical unrest ...
RICHMOND, Va. — Pharmaceutical giant Eli Lilly's recent announcement of a $5 billion plant coming to Goochland County surprised many Virginians. But for two Virginia Commonwealth University professors ...
Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis TNX-4800 was studied in a ...
TORONTO--(BUSINESS WIRE)--Conscience, a non-profit focused on accelerating drug discovery in areas of unmet medical need using open science and radical collaboration, is pleased to announce three ...
AUGUSTA, Maine (WABI) - Members of The Coalition to Protect Health Care for Rural and Underserved Communities met at the State House Wednesday to ask lawmakers to support a bill they say will protect ...
On January 27, 2026, the Department of Health and Human Services, Office of Inspector General (“OIG”) published a Special Advisory Bulletin (the “SAB”) addressing key considerations for pharmaceutical ...
first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday. The U.S. Food and Drug Administration (FDA) ...
SPOKANE, Wash. -- A new partnership is emerging with the goal of fast-tracking pharmaceutical manufacturing training in Spokane. Spokane Community College is teaming up with Jubilant HollisterStier ...
In February 2025, the Office of Inspector General (OIG) for the US Department of Health and Human Services issued favorable advisory opinions Advisory Opinion 24-10 and Advisory Opinion 24-12, ...
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is one of the 12 Small Cap Stocks with High Upside Potential. On May 12, the diversified biopharmaceutical company entered an accelerated share purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results